KRAS and cancer: High TB (≥10 tumor buds in a 20 × objective field) is present in 32% (179 of 553) of cases, and is associated with advanced pathologic stage, MSI, KRAS mutation and on multivariate analysis with a >2 times risk of cancer-specific death